|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2002-3-28
|
|
pubmed:abstractText |
Lymphocyte-predominant Hodgkin disease (LPHD) is rare and has a natural history different from that of classic Hodgkin disease. There is little information in the literature regarding the role of chemotherapy in patients with early-stage LPHD. The objective of this study was to examine recurrence free survival (RFS), overall survival (OS), and patterns of first recurrence in patients with LPHD who were treated with radiotherapy alone or with chemotherapy followed by radiotherapy.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2002 American Cancer Society.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
94
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1731-8
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:11920535-Adolescent,
pubmed-meshheading:11920535-Adult,
pubmed-meshheading:11920535-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:11920535-Combined Modality Therapy,
pubmed-meshheading:11920535-Disease-Free Survival,
pubmed-meshheading:11920535-Female,
pubmed-meshheading:11920535-Hodgkin Disease,
pubmed-meshheading:11920535-Humans,
pubmed-meshheading:11920535-Male,
pubmed-meshheading:11920535-Mechlorethamine,
pubmed-meshheading:11920535-Middle Aged,
pubmed-meshheading:11920535-Mitoxantrone,
pubmed-meshheading:11920535-Neoplasm Recurrence, Local,
pubmed-meshheading:11920535-Neoplasm Staging,
pubmed-meshheading:11920535-Prednisone,
pubmed-meshheading:11920535-Procarbazine,
pubmed-meshheading:11920535-Prognosis,
pubmed-meshheading:11920535-Retrospective Studies,
pubmed-meshheading:11920535-Treatment Outcome,
pubmed-meshheading:11920535-Vinblastine,
pubmed-meshheading:11920535-Vincristine
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
European Organization for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte very favorable and favorable, lymphocyte-predominant Hodgkin disease.
|
|
pubmed:affiliation |
Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030-4009, USA. rwilder@mdanderson.org
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Multicenter Study
|
